Sensitive on-chip detection of cancer antigen 125 using a DNA aptamer/carbon nanotube network platform
- Authors
- Gedi, Vinayakumar; Song, Chung Kil; Kim, Gae Baik; Lee, Jin Oh; Oh, Eunkyul; Shin, Bum Seok; Jung, Mingi; Shim, Jinhee; Lee, Haiwon; Kim, Young-Pil
- Issue Date
- Mar-2018
- Publisher
- Elsevier BV
- Keywords
- Aptamer; CA125; MUC16; Ovarian cancer; CNT; Immunoassay
- Citation
- Sensors and Actuators, B: Chemical, v.256, pp 89 - 97
- Pages
- 9
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Sensors and Actuators, B: Chemical
- Volume
- 256
- Start Page
- 89
- End Page
- 97
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/17738
- DOI
- 10.1016/j.snb.2017.10.049
- ISSN
- 0925-4005
1873-3077
- Abstract
- Despite the major role of cancer antigen 125 (CA125) in cancer progression, its structural diversity makes antibody-based immunoassay of this protein difficult. Here we report the selection of an anti-CA125 ssDNA aptamer and its application to sensitive detection of CA125 when used together with a CA125-specific antibody immobilized on a three-dimensional network of carbon nanotubes (3DN-CNTs). With exceptional stability and easy modifications over antibodies, the selected ssDNA aptamer (rCAA-8) showed high binding affinity (166 nM) for recombinant CA125, which enabled CA125-specific imaging in ovarian cancer cells (OVCAR-3). Furthermore, when compared to other fluorescent assays based on graphene oxide or flat surface and traditional enzyme-linked immunosorbent assay, a chip-based assay using a 3DN-CNT surface and anti-CA125 antibody-aptamer pair resulted in higher sensitivity and broader dynamic range as a function of CA125 concentration, due to high target specificity and high surface loading density. Our on-chip aptamer-based assay will facilitate sensitive and specific monitoring of CA125 in the biological and clinical fields.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 자연과학대학 > 서울 생명과학과 > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.